# Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic

> **NCT03434249** · NA · COMPLETED · sponsor: **SOFAR S.p.A.** · enrollment: 80 (actual)

## Conditions studied

- Infantile Colic
- Colic, Infantile

## Interventions

- **DIETARY_SUPPLEMENT:** Bifidobacterium, BB-12® (Bifidolactis Infant)
- **DIETARY_SUPPLEMENT:** Bifidolactis Infant Placebo

## Key facts

- **NCT ID:** NCT03434249
- **Lead sponsor:** SOFAR S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-11
- **Primary completion:** 2017-11-06
- **Final completion:** 2017-11-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03434249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03434249, "Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03434249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*